Particulars (Rupees in Crores.) | Dec-2024 | Sept-2024 | Jun-2024 | Mar-2024 | Dec-2023 |
---|---|---|---|---|---|
Gross Sales | 59.51 | 66.75 | 60.73 | 55.19 | 51.82 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 59.51 | 66.75 | 60.73 | 55.19 | 51.82 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 0.6 | 1.31 | 1.12 | 0.98 | 0.85 |
Total Income | 60.11 | 68.07 | 61.85 | 56.17 | 52.67 |
Total Expenditure | 41.26 | 43.56 | 40.13 | 36.5 | 36.51 |
PBIDT | 18.86 | 24.51 | 21.72 | 19.67 | 16.16 |
Interest | 1.98 | 2.13 | 2.22 | 2.08 | 2.03 |
PBDT | 16.87 | 22.38 | 19.51 | 17.59 | 14.14 |
Depreciation | 8.83 | 8.75 | 8.99 | 8.36 | 7.92 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 2.15 | 3.58 | 3.09 | 2.86 | 1.82 |
Deferred Tax | -0.09 | -0.1 | -0.25 | 0.05 | -0.14 |
Reported Profit After Tax | 5.98 | 10.16 | 7.67 | 6.32 | 4.54 |
Minority Interest After NP | -0.17 | -0.19 | -0.27 | -0.2 | -0.12 |
Net Profit after Minority Interest | 6.15 | 10.34 | 7.94 | 6.52 | 4.65 |
Extra-ordinary Items | 0 | 0 | 0 | -0.78 | 0 |
Adjusted Profit After Extra-ordinary item | 6.15 | 10.34 | 7.94 | 7.3 | 4.65 |
EPS (Unit Curr.) | 1.18 | 1.94 | 1.49 | 1.89 | 0.87 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 10.42 | 8.63 | 8.63 | 6.9 | 6.9 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 31.69 | 36.71 | 35.76 | 35.64 | 31.18 |
PBDTM(%) | 28.34 | 33.52 | 32.12 | 31.87 | 27.28 |
PATM(%) | 10.04 | 15.22 | 12.62 | 11.45 | 8.76 |
Suraksha Diagnostics specializes in medical consultancy services, hoping to attract investors in the rising healthcare sector
The anchor book, available to institutional investors, will open a day earlier, on November 28, 2024.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.